The larger amount of C3 and a moderate amount of C9 in ANCA-negative GN implies activation of the alternate and terminal pathways of the complement system, suggesting that this entity may be caused or promoted by a genetic or acquired defect in the alternative pathway [11]. This evidence concerns the gene C9 and ganglioneuroma.